Home > Products > API

  • Product NameAzithromycin
  • CasNo. 83905-01-5
  • MFC38H72N2O12
  • MW748.996
  • Purity
  • Appearancewhite crystalline powder
  • Packing
  • Contact usInquiry

Product Details

CasNo： 83905-01-5

MF： C38H72N2O12

Appearance： white crystalline powder

Factory Supply 99% Pure Azithromycin 83905-01-5 Efficient Transportation

  • Molecular Formula:C38H72N2O12
  • Molecular Weight:748.996
  • Appearance/Colour:white crystalline powder 
  • Vapor Pressure:2.51E-31mmHg at 25°C 
  • Melting Point:113-115 °C 
  • Refractive Index:1.536 
  • Boiling Point:822.105 °C at 760 mmHg 
  • PKA:pKa 8.74 (H2O t=25 I=0.167) (Uncertain);9.45(H2O t=25 I=0.167) (Uncertain) 
  • Flash Point:450.993 °C 
  • PSA：180.08000 
  • Density:1.184 g/cm3 
  • LogP:1.83860 

Azithromycin(Cas 83905-01-5) Usage

Description

Azithromycin is used to treat certain bacterial infections, such as bronchitis; pneumonia; sexually transmitted diseases (STD); and infections of the ears, lungs, sinuses, skin, throat, and reproductive organs.

Uses

Azithromycin is an antibiotic medicine. It's used to treat infections including: chest infections such as pneumonia. ear, nose and throat and nose infections such as sinus infection (sinusitis)

InChI:InChI=1/C38H72N2O12/c1-15-27-38(10,46)31(42)24(6)40(13)19-20(2)17-36(8,45)33(52-35-29(41)26(39(11)12)16-21(3)48-35)22(4)30(23(5)34(44)50-27)51-28-18-37(9,47-14)32(43)25(7)49-28/h20-33,35,41-43,45-46H,15-19H2,1-14H3/t20-,21-,22-,23-,24+,25-,26+,27+,28-,29-,30+,31-,32+,33+,35+,36-,37-,38+/m1/s1

83905-01-5 Relevant articles

Azithromycin Clinical Pharmacokinetics

Nestor J. Lalak & David L. Morris

Clinical Pharmacokinetics, Volume 25, pages 370–374, (1993)

A 500mg dose on day 1, followed by 250mg daily on days 2 to 5, has been demonstrated to maintain azithromycin concentrations at sites of infection and continues to be effective for several days after administration has ceased. The pharmacokinetics of azithromycin make it a drug with diverse therapeutic applications.

NOVEL ANTI-INFECTIVE AND ANTI-INFLAMMATORY COMPOUNDS

-

Page/Page column 100, (2018/09/20)

Lysosomally accumulated substances that ...

Clinical toleration and safety of azithromycin

Scott Hopkins M.D.

The American Journal of Medicine Volume 91, Issue 3, Supplement 1, 12 September 1991, Pages S40-S45

Coadministration with antacids decreased the peak serum concentration of azithromycin, but did not affect its overall absorption. Azithromycin was well tolerated in the presence of a wide variety of concurrent illnesses and medications.

83905-01-5 Upstream products

  • 50-00-0
    50-00-0

    formaldehyd

  • 64-18-6
    64-18-6

    formic acid

  • 161193-44-8
    161193-44-8

    C37H66N2O12

  • 76801-85-9
    76801-85-9

    9-Deoxo-9a-aza-9a-homoerythromycin A

83905-01-5 Downstream products

  • 592476-49-8
    592476-49-8

    carbonic acid benzyl ester 4-dimethylamino-2-[2-ethyl-3,4,10-trihydroxy-13-(4-methoxy-4,6-dimethyl-5-oxo-tetrahydro-pyran-2-yloxy)-3,5,6,8,10,12,14-heptamethyl-15-oxo-1-oxa-6-aza-cyclopentadec-11-yloxy]-6-methyl-tetrahydro-pyran-3-yl ester

  • 90503-06-3
    90503-06-3

    azithromycin-3'-N-oxide

  • 172617-84-4
    172617-84-4

    (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)‐2‐ethyl‐3,4,10‐trihydroxy‐13‐{(2R,4R,5S,6S)‐5‐hydroxy‐4‐methoxy‐4,6‐dimethyl-tetrahydropyran‐2‐yloxy}‐11‐{(2S,3R,4S,6R)‐3‐hydroxy‐6‐methyl‐4‐methylamino-tetrahydropyran‐2‐yloxy}‐3,5,6,8,10,12,14‐heptamethyl‐1‐oxa‐6‐azacyclopentadecan‐15‐one

Relevant Products

Related products

  • Product NameCasNo.